Research Article
Paediatric Germ Cell Tumours: Case Study Oncology Centre of Basra Between 2004-2015
@INPROCEEDINGS{10.4108/eai.7-9-2021.2314945, author={Nayef J. Farhan Al-Khafaji and Wasan H. Saud Al-Ibadi and Aqila A. Sahi Kadhim}, title={Paediatric Germ Cell Tumours: Case Study Oncology Centre of Basra Between 2004-2015}, proceedings={Proceedings of 2nd International Multi-Disciplinary Conference Theme: Integrated Sciences and Technologies, IMDC-IST 2021, 7-9 September 2021, Sakarya, Turkey}, publisher={EAI}, proceedings_a={IMDC-IST}, year={2022}, month={1}, keywords={germ cell tumours platinum children basra}, doi={10.4108/eai.7-9-2021.2314945} }- Nayef J. Farhan Al-Khafaji
Wasan H. Saud Al-Ibadi
Aqila A. Sahi Kadhim
Year: 2022
Paediatric Germ Cell Tumours: Case Study Oncology Centre of Basra Between 2004-2015
IMDC-IST
EAI
DOI: 10.4108/eai.7-9-2021.2314945
Abstract
The incidence of germ cell tumours (GCT) was 2.9% in all malignant tumours of children less than 16 years old with the occurrence of GCT in male to female ratio was 1.0:1.1. The main aim of this study is to exhibit the outcome and treatment of children less than 16 years old in Basra Oncology Centre in Iraq between 2004-2015. In the oncology Centre of Basra 45 cases of GCT age 1 to 156 months (mean 78.5 months). The sample divide as a following, female 24 (46.7%) and male 21(53.3%) with gonadal 21(46.7%) testes 9(20%) and ovary 12(26.7%). Histologically, in our data, the most common GCT was teratomas 2 mature teratomas these two cases were excluded from the current study, 20 cases immature 44.4%, followed by yolk sac tumours nineteen cases (n:19=42.2%), dysgerminoma (n: 4=8.9%) and embryonal carcinoma (n: 2=4.4%). Based on the results, about 5 years overall survival (OS) is 88.9%. During the previous years, the surgical, chemotherapy, and radiotherapy guidelines for (GCT) have been purified to decrease the early and late morbidities and associated with improving survival. Used of Platinum (carboplatin /cisplatin) the outcome of children with (GCT) has improved 5-year survival.